Blurbs

Analysts Offer Insights on Healthcare Companies: and Blueprint Medicines (BPMC)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Blueprint Medicines (BPMCResearch Report) with bullish sentiments.

Blueprint Medicines (BPMC)

In a report issued on August 17, Joel Beatty from Robert W. Baird maintained a Buy rating on Blueprint Medicines, with a price target of $96.00. The company’s shares closed last Tuesday at $71.68.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 4.9% and a 51.0% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $88.67 average price target, implying a 23.2% upside from current levels. In a report issued on August 2, Raymond James also maintained a Buy rating on the stock with a $115.00 price target.

See the top stocks recommended by analysts >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos